Gabapentin use and a claim for memory loss in Delaware

Delaware holds outsized importance in gabapentin litigation because many pharmaceutical companies, including generic gabapentin manufacturers, are incorporated in the state. The Delaware Court of Chancery and Superior Court have deep experience with pharmaceutical corporate governance and product liability matters. Delaware's small population of approximately 1 million means fewer total claimants, but the state's corporate jurisdiction creates legal leverage that extends far beyond its borders. Delaware's gabapentin prescribing rates are moderate, with higher concentrations in downstate Sussex and Kent counties where chronic pain prevalence and opioid crisis impact are elevated relative to the Wilmington metro area.

For the overall process and updates, read the Gabapentin use and a claim for memory loss overview. This page covers the local information available for Delaware.